Literature DB >> 12848792

Higher energy monophasic DC cardioversion for persistent atrial fibrillation: is it time to start at 360 joules?

C Boos1, M D Thomas, A Jones, E Clarke, G Wilbourne, R S More.   

Abstract

BACKGROUND: Electrical direct-current cardioversion (DCCV) has become a routine therapy for atrial fibrillation (AF), although some uncertainty remains regarding the optimal energy settings. AIMS: This study examines whether the use of a higher initial energy monophasic shock of 360 joules (J) for external DCCV, in patients with persistent AF would prove more effective, yet as safe, as the use of a lower initial energy 200 J shock.
METHODS: A cohort of 107 patients with persistent AF was prospectively randomized to an initial synchronized DCCV shock of 360 J versus 200 J (n = 50 vs 57), followed by a similar shock sequence thereafter of four further shocks of 360 J for the two groups. In all patients the levels of troponin I (cTnI) were measured precardioversion and 18-20 hours later, the following day. In a subgroup of 36 patients in each group, the levels of creatine kinase (CK) and aspartate transaminase (AST) were measured pre- and 18-20 hours postcardioversion.
RESULTS: The success rate for DCCV was significantly higher in the 360 J group compared to the 200 J group (96.0% vs 75.4%, P = 0.003). The mean CK IU/L levels (1137.5.0 vs 2411.8, P = 0.014) and AST levels (39.83 vs 52.86, P = 0.010) were significantly lower in the 360 J group compared to the 200 J group. There was no statistical rise in cTnI (microg/L) in either group (P = 1.00). The average number of shocks delivered (1.84 vs 2.56, P = 0.006) was significantly less in the 360 J group than in the 200 J group, although total energy requirements for DCCV were similar for the two groups (662.4 J vs 762.4 J, P = 0.67).
CONCLUSION: For patients with persistent AF the use of a higher initial-energy monophasic shock of 360 J achieves a significantly greater success rate, with less skeletal muscle damage (and no cardiac muscle damage) as compared with the traditional starting energy of a 200 J DC shock.

Entities:  

Mesh:

Year:  2003        PMID: 12848792      PMCID: PMC6932216          DOI: 10.1046/j.1542-474x.2003.08205.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  24 in total

1.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

2.  Factors determining success and energy requirements for cardioversion of atrial fibrillation.

Authors:  G W Dalzell; J Anderson; A A Adgey
Journal:  Q J Med       Date:  1990-09

3.  Enzyme release after elective cardioversion.

Authors:  J Jakobsson; I Odmansson; R Nordlander
Journal:  Eur Heart J       Date:  1990-08       Impact factor: 29.983

4.  Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation.

Authors:  C Schmitt; E Alt; A Plewan; R Ammer; M Leibig; M Karch; A Schömig
Journal:  J Am Coll Cardiol       Date:  1996-10       Impact factor: 24.094

Review 5.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association.

Authors:  E N Prystowsky; D W Benson; V Fuster; R G Hart; G N Kay; R J Myerburg; G V Naccarelli; D G Wyse
Journal:  Circulation       Date:  1996-03-15       Impact factor: 29.690

6.  Metabolic changes and mitochondrial dysfunction early following transthoracic countershock in dogs.

Authors:  T G Trouton; J D Allen; L K Yong; J J Rooney; A A Adgey
Journal:  Pacing Clin Electrophysiol       Date:  1989-11       Impact factor: 1.976

7.  Cardiac troponin I does not increase after cardioversion.

Authors:  E Bonnefoy; P Chevalier; G Kirkorian; J Guidolet; A Marchand; P Touboul
Journal:  Chest       Date:  1997-01       Impact factor: 9.410

8.  Epidemiologic features of chronic atrial fibrillation: the Framingham study.

Authors:  W B Kannel; R D Abbott; D D Savage; P M McNamara
Journal:  N Engl J Med       Date:  1982-04-29       Impact factor: 91.245

9.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

10.  Cardiac troponin T does not increase after electrical cardioversion for atrial fibrillation or atrial flutter.

Authors:  K Greaves; T Crake
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

View more
  2 in total

1.  A short course of oral amiodarone improves sinus rhythm maintenance post-cardioversion for atrial fibrillation.

Authors:  C Boos; J Ritzema; R S More
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Non-invasive atrial fibrillation organization follow-up under successive attempts of electrical cardioversion.

Authors:  Raúl Alcaraz; José Joaquín Rieta; Fernando Hornero
Journal:  Med Biol Eng Comput       Date:  2009-12       Impact factor: 2.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.